
United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure
pharmafile | April 9, 2019 | News story | Manufacturing and Production, Research and Development |Â Â Tyvaso, United Therapeutics, pharma, pulmonary arterial hypertensionÂ
United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) therapy failed to meet its primary endpoint at Phase 3, it has decided to discontinue all further development of the product.
The company sought to prove the efficacy of oral esuberaprost tablets when added to its inhaled therapy Tyvaso (treprostinil) compared to Tyvaso alone. However, it was found that esuberaprost failed to delay time until first clinical worsening event such as death or hospitalisation from disease worsening, falling short of the trial’s primary endpoint.
Secondary endpoints included six-minute walking distance, WHO functional class and Borg dyspnoea score.
United Therapeutics is now disadvantaged in the PAH space, after the launch by Sandoz of the first generic version of the company’s own injectable treprostinil therapy Remodulin in March.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

NICE recommends sotatercept for pulmonary arterial hypertension
The National Institute for Health and Care Excellence (NICE) has recommended Winrevair (sotatercept) as a …






